| MESOBLAST SP.ADRS 144A/10 |
| USA |
| Gesundheit |
| US5907174016 / A4004R |
| LWB1 (Frankfurt) / MESO (NASDAQ) |
| FRA:LWB1, ETR:LWB1, LWB1:GR, NASDAQ:MESO |
| - |
| https://www.mesoblast.com.. |
|
Mesoblast Ltd. Sponsored ADR represents shares in Mesoblast Limited, an Australian biopharmaceutical company focused on developing innovative cellular medicines. The company’s primary aim is to address complex medical conditions involving significa..
>Volltext.. |
| 1750.64 Mio. EUR |
| 1755.11 Mio. EUR |
| 56.72 Mio. EUR |
| -55.88 Mio. EUR |
| -81.83 Mio. EUR |
| -0.64 EUR |
| 117.08 Mio. EUR |
| 112.6 Mio. EUR |
| -60.71 Mio. EUR |
| 1.01 |
| 1055.07% |
| 8.58% |
| - |
| - |
| - |
| - |
| MESOBLAST ADR, MESOBLAST |
| 04.04.26 |
|